

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

LISTING OF CLAIMS:

- 1.(currently amended) ~~Use of a polyurethane in the manufacturing of~~ A method of preparing a composition or kit used for filling or short-circuiting vascular cavities, which comprises using an effective amount of a polyurethane, which ~~where the polyurethane used~~ can be dissolved in a solvent or a solvent mixture mingling with body fluids.
- 2.(currently amended) The ~~[[use]]~~ method according to claim 1, where a composition is manufactured, which contains the polyurethane dissolved in a solvent or a solvent mixture mingling with body fluids, optionally combined with usual auxiliaries.
- 3.(currently amended) The ~~[[use]]~~ method according to claim 1, where a kit is manufactured, which contains the following components: a) a polyurethane which can be dissolved in a solvent or a solvent mixture mingling with body fluids, b) one or more solvents or solvent mixtures mingling with body fluids, in which the said polyurethane can be dissolved, c) optionally other usual auxiliaries, where the components given above are formulated separately or some of them are formulated in a common subunit.
- 4.(currently amended) The ~~[[use]]~~ method according to claim 1 ~~any of claims 1 to 3~~, where the solvent is DMSO or EtOH or their mixture, preferably the mixture of them in the volume ratio of 1: 10-10: 1, more preferably of 1: 3-3: 1.
- 5.(currently amended) The ~~[[use]]~~ method according to claim 1 ~~any of claims 1 to 4~~, where the main diol component of the polyurethane is characterized by the general formula of HO-R'-

OH, where R' stands for a C1-C8 alkylene group, preferably 1,4-buthanediol.

6.(currently amended) The [[use]]method according to claim 5, where 50 to 95 % of the main diol component is in polyether form, preferably in polytetrahydrofuran form.

7.(currently amended) The [[use]]method according to claim 1 ~~claims 1 to 6~~, where the main diisocyanate component of the polyurethane is one or more compound selected from the following ones: 2, 4- or 2, 6- toluylene-diisocyanate (TDI), 1,6-hexane-diisocyanate and diphenyl-methane-4, 4'-diisocyanate (MDI), of which diphenyl-methane-4,4'-diisocyanate is preferred.

8.(currently amended) The [[use]]method according to claim 1 ~~any of claims 1 to 7~~, where the composition or kit contains a polyurethane solution, usable for filling aneurisms, having viscosity higher than 150 mPa. s, preferably higher than 250 mPa. s at 23 °C.

9.(currently amended) The [[use]]method according to claim 1 ~~any of claims 1 to 7~~, where the composition or kit contains a polyurethane solution, usable for filling angiomas and vascularized tumors, having viscosity is lower than 1 000 mPa. s, preferably lower than 250 mPa. s at 23 °C.

10.(currently amended) The [[use]]method according to claim 1 ~~any of claims 1 to 9~~, where the molecular mass of the polyurethane used is 4 000 to 70 000 Dalton, preferably 20 000 to 35 000 Dalton.

11.(currently amended) The [[use]]method according to claim 1 ~~any of claims 1 to 10~~, where the composition or kit contains contrast material as an auxiliary, preferably selected from the following group: a substance containing tantalum, iodine, barium, tungsten and/or bismuth, of which micronized tantalum powder, tantalum-oxide, barium-sulphate and tungsten are more preferred.

12.(original) Composition for filling or short-circuiting vascular cavities, containing a polyurethane which can be dissolved in a solvent or a solvent mixture mingling with body fluids, optionally dissolved in a solvent or a solvent mixture mingling with body fluids, and optionally combined with usual auxiliaries.

13.(original) A composition according to claim 12, which contains the polyurethane dissolved in a solvent or a solvent mixture mingling with body fluids, optionally combined with usual auxiliaries.

14.(original) A therapeutic product containing the components formulated separately (kits of parts), which can be used for filling or short-circuiting vascular cavities and contains the following: a) a polyurethane that can be solved in a solvent or a solvent mixture mingling with body fluids, b) one or more solvents or solvent mixtures mingling with body fluids, in which the said polyurethane can be dissolved, c) optionally other usual auxiliaries, where the components given above are formulated separately or some of them are formulated in a common subunit.

15.(currently amended) A composition or a therapeutic product according to claim 12 ~~any of claims 12 to 14~~, where the solvent is DMSO or EtOH or their mixture, preferably a mixture of them in the volume ratio of 1: 10-10: 1, more preferably of 1: 3-3: 1.

16.(currently amended) A composition or a therapeutic product according to claim 12 ~~any of claims 12 to 15~~, where the main diol component of the polyurethane is characterized by the general formula of HO-R'-OH, where R stands for a C- C8 alkylene group, preferably 1,4-buthanediol.

17.(original) A composition or a therapeutic product according to 16, where 50 to 95 % of the main diol component is in polyether form, preferably in polytetrahydrofurane form.

18.(currently amended) A composition or a therapeutic product according to claim 12 ~~any of claims 12 to 17~~, where the main diisocyanate component of the polyurethane is one or more selected from the following ones: 2, 4- or 2,6- toluylene-diisocyanate (TDI), 1,6-hexane-diisocyanate and diphenyl-methane-4,4'-diisocyanate (MDI), of which diphenyl-methane-4,4'-diisocyanate is preferred.

19.(currently amended) A composition or a therapeutic product according to claim 12 ~~any of claims 12 to 18~~, where the composition or therapeutic product contains a polyurethane solution, usable for filling aneurisms, having viscosity higher than 150 mPa. s, preferably 250 mPa. s at 23 °C.

20.(currently amended) A composition or a therapeutic product according to claim 12 ~~any of claims 12 to 18~~, where the composition or therapeutic product contains a polyurethane solution, usable for filling angiomas and vascularized tumors, having viscosity lower than 1 000 mPa. s, preferably lower than 250 mPa. s at 23 °C.

21.(currently amended) A composition or a therapeutic product according to claim 12 ~~any of claims 12 to 20~~, where the molecular mass of the polyurethane used is 4 000 to 70 000 Dalton, preferably 20 000 to 35 000 Dalton.

22.(currently amended) A composition or a therapeutic product according to claim 12 ~~any of claims 12 to 21~~, where the composition or therapeutic product contains contrast material as an auxiliary, preferably selected from the following group: a substance containing tantalum, iodine, barium, tungsten or bismuth, of which micronized tantalum powder, tantalum-oxide, barium-sulphate and tungsten are more preferred.

23.(currently amended) ~~Use of a polyurethane for~~ A method of filling vascular cavities, which comprises applying an effective amount of polyurethane to the cavities, where the applied polyurethane is dissolved in a solvent or solvent

mixture mingling with body fluids, and optionally combined with usual auxiliaries.

24.(currently amended) The ~~[[use]]~~ method according to claim 23, where the solvent is either DMSO or EtOH or their mixture, preferably a mixture of them in the volume ratio of 1: 10-10: 1, more preferably of 1: 3-3: 1.

25.(currently amended) The ~~[[use]]~~ method according to claim 23 ~~any of claims 23 and 24~~, where the main diol component of the polyurethane is a diol characterized by the general formula of HO-R'-OH, where RI stands for a C1-C8 alkanediyl group, preferably 1,4-buthanediol.

26.(currently amended) The ~~[[use]]~~ method according to claim 25, where 50 to 95 % of the main diol component is in polyether form, preferably in polytetrahydrofuran form.

27.(currently amended) The ~~[[use]]~~ method according to claim 23 ~~any of claims 23 to 26~~, where the main diisocyanate component of the polyurethane is one or more compound selected from the following ones: 2, 4- or 2, 6-toluylene-diisocyanate (TDI), 1,6-hexane-diisocyanate and diphenyl-methane-4, 4'-diisocyanate (MDI), of which diphenyl-methane- 4,4'-diisocyanate is preferred.

28.(currently amended) The ~~[[use]]~~ method according to claim 23 ~~any of claims 23 to 27~~, where a polyurethane solution applicable for filling aneurisms is used having viscosity higher than 150 mPa. s, preferably 250 mPa. s at 23 °C.

29.(currently amended) The ~~[[use]]~~ method according to claim 23 ~~any of claims 23 to 27~~, where a polyurethane solution applicable for filling angiomas and vascularized tumors is used having viscosity lower than 1 000 mPa. s, preferably lower than 250 mPa. s at 23 °C.

30.(currently amended) The ~~[[use]]~~ method according to claim 23 ~~any of claims 23 to 29~~, where molecular mass of the polyurethane used is 4 000-70 000 Dalton, preferably 20 000-35 000 Dalton.

31.(currently amended) The ~~[[use]]~~ method according to claim 23 ~~any of claims 23-30~~, where contrast material is used as an auxiliary, preferably selected from the following group: a substance containing tantalum, iodine, barium, tungsten or bismuth, of which micronized tantalum powder, tantalum-oxide, barium-sulphate and tungsten are more preferred.